Filing Details
Aprea Therapeutics, Inc. (NASDAQ:APRE) filed a Form 8-K with the Securities and Exchange Commission on August 12, 2026, disclosing a material event.
8k filedNASDAQ:APRE
Aprea Therapeutics, Inc. (APRE) Reports Material Event to SEC
Aprea Therapeutics, Inc. (NASDAQ:APRE) filed a Form 8-K with the Securities and Exchange Commission on August 12, 2026, disclosing a material event.
At publication ·
What changed
Aprea Therapeutics, Inc. (NASDAQ:APRE) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Aprea Therapeutics filed a Form 8-K with the SEC on August 12, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing summary.
- The company's stock trades at $0.68 per share with a market capitalization of $6.4 million, indicating a very small-cap healthcare company.
Market Context
Aprea Therapeutics, Inc.'s stock currently trades at $0.68 with a market capitalization of $6.4M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Aprea Therapeutics, Inc.'s stock.
All SEC filings for Aprea Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View APRE Stock Page
Frequently Asked Questions
Where can I read APRE's SEC filings?
Browse all filings on our APRE SEC filings page.
What types of SEC filings does Aprea Therapeutics, Inc. file?
Public companies like Aprea Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.